Monoclonal antibodies directed against human FcRn and their applications.

Gregory J. Christianson, Victor Z. Sun, Shreeram Akilesh, Emanuele PESAVENTO, Gabriele Proetzel, Derry C. Roopenian

Research output: Contribution to journalArticlepeer-review

31 Citations (Scopus)


The MHC class I-like Fc receptor (FcRn) is an intracellular trafficking Fc receptor that is uniquely responsible for the extended serum half-life of antibodies of the IgG subclass and their ability to transport across cellular barriers. By performing these functions, FcRn affects numerous facets of antibody biology and pathobiology. Its critical role in controlling IgG pharmacokinetics has been leveraged for the design of therapeutic antibodies and related biologics. FcRn also traffics serum albumin and is responsible for the enhanced pharmacokinetic properties of albumin-conjugated therapeutics. The understanding of FcRn and its therapeutic applications has been limited by a paucity of reliable serological reagents against human FcRn. Here, we describe the properties of a new panel of highly specific monoclonal antibodies (mAbs) directed against human FcRn with diverse epitope specificities. We show that this antibody panel can be used to study the tissue expression pattern of human FcRn, to selectively block IgG and serum albumin binding to human FcRn in vitro and to inhibit FcRn function in vivo. This mAb panel provides a powerful resource for probing the biology of human FcRn and for the evaluation of therapeutic FcRn blockade strategies.
Original languageEnglish
Pages (from-to)208-216
Number of pages9
Issue number2
Publication statusPublished - 1 Mar 2012


  • Albumin
  • FcRn
  • IgG
  • monoclonal antibody


Dive into the research topics of 'Monoclonal antibodies directed against human FcRn and their applications.'. Together they form a unique fingerprint.

Cite this